Trial
NCT04605614
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Hematopoietic and Lymphoid Cell Neoplasm
Intervention
Copper Cu 64-DOTA-pembrolizumab
Why stopped
slow accruals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-09